Literature DB >> 22116556

The anticoagulant function of coagulation factor V.

Thomas J Cramer1, Andrew J Gale.   

Abstract

Almost two decades ago an anticoagulant function of factor V (FV) was discovered, as an anticoagulant cofactor for activated protein C (APC). A natural mutant of FV in which the R506 inactivation site was mutated to Gln (FV(Leiden)) was inactivated slower by APC, but also could not function as anticoagulant cofactor for APC in the inactivation of activated factor VIII (FVIIIa). This mutation is prevalent in populations of Caucasian descent, and increases the chance of thrombotic events in carriers. Characterisation of the FV anticoagulant effect has elucidated multiple properties of the anticoagulant function of FV: 1) Cleavage of FV at position 506 by APC is required for anticoagulant function. 2) The C-terminal part of the FV B domain is required and the B domain must have an intact connection with the A3 domain of FV. 3) FV must be bound to a negatively charged phospholipid membrane. 4) Protein S also needs to be present. 5) FV acts as a cofactor for inactivation of both FVa and FVIIIa. 6) The prothrombotic function of FV(Leiden) is a function of both reduced APC cofactor activity and resistance of FVa to APC inactivation. However, detailed structural and mechanistic properties remain to be further explored.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22116556     DOI: 10.1160/TH11-06-0431

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  18 in total

Review 1.  Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway.

Authors:  E A M Bouwens; F Stavenuiter; L O Mosnier
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

2.  Survival advantage of heterozygous factor V Leiden carriers in murine sepsis.

Authors:  E Kerschen; I Hernandez; M Zogg; M Maas; H Weiler
Journal:  J Thromb Haemost       Date:  2015-03-31       Impact factor: 5.824

3.  Characterization of Platelet Function-Related Gene Predicting Survival and Immunotherapy Efficacy in Gastric Cancer.

Authors:  Yan Xia; Xin Lin; Yangyang Cheng; Huimin Xu; Jingya Zeng; Wanlin Xie; Mingzhu Wang; Yihua Sun
Journal:  Front Genet       Date:  2022-06-28       Impact factor: 4.772

4.  Down-regulation of the clotting cascade by the protein C pathway.

Authors:  Fabian Stavenuiter; Eveline A M Bouwens; Laurent O Mosnier
Journal:  Hematol Educ       Date:  2013

5.  Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice.

Authors:  Hai Po H Liang; Edward J Kerschen; Sreemanti Basu; Irene Hernandez; Mark Zogg; Shuang Jia; Martin J Hessner; Raffaella Toso; Alireza R Rezaie; José A Fernández; Rodney M Camire; Wolfram Ruf; John H Griffin; Hartmut Weiler
Journal:  Blood       Date:  2015-09-04       Impact factor: 22.113

6.  Pneumococcal meningitis and endocarditis in an infant: possible improved survival with factor V Leiden mutation.

Authors:  Sitikant Mohapatra; Assaf Doulah; Elspeth Brown
Journal:  Eur J Pediatr       Date:  2017-08-12       Impact factor: 3.183

7.  Polymorphisms at activated protein C cleavage sites of factor V: Are they important in the absence of factor V Leiden?

Authors:  Ehsan Kheradmand; Shaghayegh Haghjooy-Javanmard; Leila Dehghani; Mohammad Saadatnia
Journal:  Iran J Neurol       Date:  2017-01-05

8.  Clinical Significance of Detection of Coagulation Indexes, Immune Factors and Inflammatory Factors in Patients with Pregnancy-Induced Hypertension Syndrome in China.

Authors:  Fengmei Shi; Aijun Yu; Limei Yuan
Journal:  Iran J Public Health       Date:  2019-04       Impact factor: 1.429

9.  Cryo-EM structures of human coagulation factors V and Va.

Authors:  Eliza A Ruben; Michael J Rau; James A J Fitzpatrick; Enrico Di Cera
Journal:  Blood       Date:  2021-06-03       Impact factor: 25.476

10.  Mechanistic phenotypes: an aggregative phenotyping strategy to identify disease mechanisms using GWAS data.

Authors:  Jonathan D Mosley; Sara L Van Driest; Emma K Larkin; Peter E Weeke; John S Witte; Quinn S Wells; Jason H Karnes; Yan Guo; Lisa Bastarache; Lana M Olson; Catherine A McCarty; Jennifer A Pacheco; Gail P Jarvik; David S Carrell; Eric B Larson; David R Crosslin; Iftikhar J Kullo; Gerard Tromp; Helena Kuivaniemi; David J Carey; Marylyn D Ritchie; Josh C Denny; Dan M Roden
Journal:  PLoS One       Date:  2013-12-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.